Biomed Industries, Inc.
Quick facts
Phase 3 pipeline
- Biological: oral polio vaccine · Immunology / Infectious Disease
Oral polio vaccine stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by delivering live attenuated (weakened) virus that replicates in the gastrointestinal tract. - Bionetide · Other
- Comparable Placebo of drug
A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect. - NA-831 · Diabetes
NA-831 is a small molecule drug that targets the SGLT2 receptor.
Phase 2 pipeline
- Drug: Bionetide
- Drug: NA-831 · Diabetes
NA-831 is a small molecule that targets the SGLT2 receptor. - NA-931
- NA-931, dose 1, daily and orally
- NA-931 dose 3, daily and orally
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Biomed Industries, Inc.
What is Biomed Industries, Inc.'s pipeline?
Biomed Industries, Inc. has 4 drugs in Phase 3, 5 in Phase 2, 0 in Phase 1. Late-stage candidates include Biological: oral polio vaccine, Bionetide, Comparable Placebo of drug, NA-831.
Related
- Sector hub: All tracked pharma companies